Provided by Tiger Trade Technology Pte. Ltd.

DexCom

90.61
-0.4500-0.49%
Volume:728.00K
Turnover:66.15M
Market Cap:34.19B
PE:35.72
High:92.34
Open:90.83
Low:90.14
Close:91.06
52wk High:92.59
52wk Low:54.11
Shares:377.36M
Float Shares:376.00M
Volume Ratio:0.39
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.54
EPS(LYR):2.09
ROE:38.49%
ROA:10.33%
PB:13.04
PE(LYR):43.36

Loading ...

TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating

MT Newswires Live
·
Jun 10

TD Cowen Remains a Buy on Dexcom (DXCM)

TIPRANKS
·
Jun 10

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2026-06-09

Reuters
·
Jun 10

Dexcom (DXCM) Gets a Buy from Wells Fargo

TIPRANKS
·
Jun 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY)

TIPRANKS
·
Jun 09

Bellevue says obesity, diabetes drug market shifts focus to patient adherence at ADA 2026

Reuters
·
Jun 09

U.S. RESEARCH ROUNDUP- Apple, Lennar, Toll Brothers

Reuters
·
Jun 09

DexCom Inc. Stock Climbs 5.2%, Outperforms Peers

Dow Jones
·
Jun 09

DexCom price target raised to $91 from $81 at Raymond James

TIPRANKS
·
Jun 09

Movement Alert|DexCom Rises 5.27% in Regular Trading, Connect Study Data Demonstrates Significant Blood Sugar Reduction With G7 Combination Therapy

Market Focus
·
Jun 08

Mizuho Securities Adjusts DexCom Price Target to $85 From $75, Maintains Outperform Rating

MT Newswires Live
·
Jun 08

DexCom announces results from CONNECT trial of Dexcom G7

TIPRANKS
·
Jun 08

Skip the Oura Ring IPO. Buy These 10 Stocks Instead.

InvestorPlace
·
Jun 07

BRIEF-Dexcom Says Use Of Dexcom G7 Leads To Improvement In Glucose Control In People With Type 2 Diabetes Not Using Insulin Versus Routine Care Control Group

Reuters
·
Jun 07

Dexcom Connect Study: the Most Significant Clinical Study Demonstrating Cgm Benefits for People With Type 2 Diabetes Not Using Insulin

THOMSON REUTERS
·
Jun 07

Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

Reuters
·
Jun 07

Dexcom: Six-Month Extension Phase of Connect Randomized Controlled Trial Is Currently Being Conducted

THOMSON REUTERS
·
Jun 07

Dexcom: in Participants Using Glp-1S, Using Dexcom G7 Resulted in 1.4% Reduction in a1c VS 0.2% in Control Group

THOMSON REUTERS
·
Jun 07

Dexcom: Connect Study Showed Clinically Significant Reduction in a1c When Using Dexcom G7 With Various Combinations Like Metformin, Glp-1S & Sglt2s

THOMSON REUTERS
·
Jun 07

DexCom EVP, Chief Commercial Officer Jon Coleman disposes of common shares worth $726,358.43

Reuters
·
Jun 06